HEALTH-RELATED QUALITY OF LIFE IN MODERATE-TO-SEVERE PLAQUE PSORIASIS PATIENTS IN BRAZIL
Author(s)
Lopes N1, Gontijo B2, Romiti R3, Santana PK4, Machado P1
1Novartis Biociências SA, Sao Paulo, Brazil, 2Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil, 3Hospital das Clínicas University of São Paulo (USP), São Paulo, Brazil, 4Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
OBJECTIVES:: To assess the impact of moderate-to-severe plaque psoriasis on patient health-related quality of life (HRQoL). METHODS:: This was a cross-sectional, observational and multicenter study enrolling Brazilian patients with moderate-to-severe plaque psoriasis. Data were collected between December/2015 and November/2016 in 10 specialized centers. Severity was defined according to physician evaluation. Data regarding HRQoL were obtained through two instruments: EuroQol-5D questionnaire (EQ-5D-3L) and Dermatology Life Quality Index questionnaire (DLQI). EQ-5D-3L also includes a Visual Analogue Scale (EQ-VAS), which ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). RESULTS:: The study included 188 patients. Most of them were female (52.1%), Caucasian/white (68.6%) and married/stable union (61.7%). The mean age at study visit and at disease onset were 48 (±13.1) and 33 (±16) years, respectively. The leading comorbidities were hypertension (46.2%), dyslipidemia (39.3%) and psoriatic arthritis (31.0%). All patients answered DLQI and 176 (93.6%) provided valid responses for EQ-5D-3L. The mean DLQI score was 7.2 (±6.8). According to the DLQI categories, disease had no effect at all in 26.6% patients, small effect in 22.9%, moderate effect in 23.4%, very large effect in 20.7% and extremely large effect in 6.4%. The highest effect was found for “symptoms and feelings” domain (Mean 2.4 ±1.7) and the lowest in “work and school” domain (Mean 0.4 ±0.8). The EQ-5D index was 0.70 (±0.27). The dimensions “anxiety and depression” and “pain and discomfort” presented the highest quality of life impairment, in which 14.2% and 5.7% of patients reported to have extreme problems and 46.6% and 49.4% some problems, respectively. “Self-care” was the least affected dimension, with 88.1% of responders reporting absence of problems. Overall score of EQ-VAS was 68.7 (±22.3). CONCLUSIONS:: Moderate-to-severe psoriasis negatively affects Brazilian patients’ HRQoL, especially in terms of anxiety and depression as well as pain and discomfort.
Conference/Value in Health Info
2017-09, ISPOR Latin America 2017, Sao Paulo, Brazil
Value in Health, Vol. 20, No. 9 (October 2017)
Code
PSY33
Topic
Patient-Centered Research
Topic Subcategory
Patient-reported Outcomes & Quality of Life Outcomes
Disease
Sensory System Disorders, Systemic Disorders/Conditions